Robert K. Hills

H, Eath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Extended aromatase inhibitor therapy for early breast cancer - Authors' reply.

Extended aromatase inhibitor therapy for early breast cancer - Authors' reply.

Journal: Lancet (London, England)

Published: December 18, 2025

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial.

Journal: Blood

Published: December 05, 2025

Seeing something new or with new eyes?

Seeing something new or with new eyes?

Journal: British journal of haematology

Published: August 21, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood

Published: August 19, 2025

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial.

Journal: Blood

Published: July 28, 2025

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.

Journal: Blood

Published: July 28, 2025

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 18, 2024

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.

Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2024

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Journal: Journal of hematology & oncology

Published: May 19, 2024

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Journal: The Lancet. Haematology

Published: May 01, 2024

Prognostic impact of CEBPA mutational subgroups in adult AML.

Prognostic impact of CEBPA mutational subgroups in adult AML.

Journal: Leukemia

Published: October 30, 2023

Showing 1-12 of 149

Last Updated: 09/26/2026